Understanding Tysabri and PML: Key Risk Factors and Warning Signs

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Targeted Risk Assessment

If you or a loved one is taking Tysabri, understanding the risk of Progressive Multifocal Leukoencephalopathy (PML) is crucial. This condition, caused by the John Cunningham virus, can lead to severe neurological symptoms. The legacy of pharmaceutical risk communication has evolved to emphasize patient-specific factors, and this page provides a clear overview of the known risk factors and early warning signs of PML in Tysabri users.

Clinical Presentation and Diagnosis of PML

PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals. It is caused by the JC virus and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Early symptoms can be subtle and may include progressive weakness on one side of the body, clumsiness, visual disturbances, changes in thinking or memory, and confusion. Because these symptoms can mimic a multiple sclerosis relapse, diagnosis requires a high index of suspicion. Confirmation typically involves brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. In some cases, brain biopsy may be necessary. The clinical course is often rapid, with neurological deterioration occurring over weeks to months.

Tysabri Pharmacology and Reported Adverse Effects

Tysabri is a monoclonal antibody that binds to alpha-4 integrin on the surface of immune cells, preventing their migration from the bloodstream into the brain and gut. This mechanism reduces inflammation in MS and Crohn's disease but also impairs normal immune surveillance of the central nervous system. The resulting immunosuppression in the brain creates an environment where JC virus can reactivate and cause PML. In clinical trials, PML occurred in three patients who received Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Two cases were observed among 1869 MS patients treated for a median of 120 weeks; both had also received interferon beta-1a. The third case occurred after eight doses in one of 1043 Crohn's disease patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These data underscore that PML risk is present even in the absence of other immunosuppressants, though prior use of immunosuppressants is an additional risk factor.

Mechanistic Pathways Linking Tysabri to PML

The primary mechanism is the reduction of immune cell trafficking into the central nervous system. By blocking alpha-4 integrin, Tysabri prevents T cells and other immune cells from crossing the blood-brain barrier. This diminishes the brain's ability to control JC virus replication. The virus, which is latent in most adults, can then reactivate and infect oligodendrocytes, the cells that produce myelin. Destruction of these cells leads to the demyelinating lesions characteristic of PML. Three established risk factors for PML in Tysabri-treated patients are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adequacy of Warnings and Legal Implications

The prescribing information for Tysabri includes a boxed warning stating that the drug increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning explicitly identifies the three risk factors and advises that these should be considered in the context of expected benefit when initiating and continuing treatment. It also instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether prescribers and patients fully understood the magnitude of risk, particularly in the context of combination therapy or prolonged use.

Attorney-Related Considerations for Affected Patients

For patients who develop PML after Tysabri treatment, legal considerations often focus on whether the warnings provided were adequate and whether the drug was used appropriately. Key factors in potential litigation include: whether the patient was tested for anti-JCV antibodies before and during treatment; whether the duration of therapy was monitored; whether prior immunosuppressant use was documented; and whether symptoms were promptly evaluated. The timeline between exposure and documented harm is critical. PML can occur after a variable duration of Tysabri therapy, with risk increasing after two years. In clinical trials, cases occurred after 8 to 120 weeks of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who develop PML may face catastrophic neurological injury, including permanent disability or death. Legal claims may allege that the manufacturer failed to adequately warn about the risk, or that healthcare providers failed to monitor appropriately. Settlement criteria in such cases often depend on the severity of injury, the degree of adherence to risk mitigation protocols, and the strength of evidence linking the harm to Tysabri use.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and why is it associated with PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus, due to its mechanism of reducing immune cell trafficking into the central nervous system.

What are the key risk factors for developing PML while on Tysabri?

The three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the boxed warning for Tysabri.

What legal criteria are considered in Tysabri PML lawsuits?

Settlement criteria typically include the severity of injury, adherence to risk mitigation protocols (e.g., JCV antibody testing, monitoring), and evidence linking PML to Tysabri use. Legal claims may focus on inadequate warnings or failure to monitor.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.